← Back to Search

Intraocular Lens

Clareon Toric vs Eyhance Toric

N/A
Waitlist Available
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 3 postoperative visit
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing new lenses used in cataract surgery to help people see better. It involves adults who have cataracts in both eyes. The new lenses replace the cloudy ones removed during surgery, helping patients see clearly again.

Eligible Conditions
  • Cataract
  • Pseudoaphakia
  • Aphakia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 3 postoperative visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 3 postoperative visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Binocular Best-corrected Distance Visual Acuity (BCDVA) at 4 Meters Under Bright Lighting Conditions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Clareon/Clareon ToricExperimental Treatment3 Interventions
Phacoemulsification surgery, followed by implantation with Alcon Clareon Aspheric Hydrophobic Acrylic IOL or Alcon Clareon Aspheric Hydrophobic Acrylic Toric IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
Group II: Eyhance/Eyhance ToricActive Control3 Interventions
Phacoemulsification surgery, followed by implantation with TECNIS Eyhance IOL or TECNIS Eyhance Toric II IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clareon Toric IOL
2022
N/A
~210
Clareon IOL
2022
N/A
~210
Phacoemulsification surgery
2013
N/A
~270

Find a Location

Who is running the clinical trial?

Alcon ResearchLead Sponsor
732 Previous Clinical Trials
128,656 Total Patients Enrolled
119 Trials studying Cataract
20,834 Patients Enrolled for Cataract
Clinical Trial Lead, CDMA SurgicalStudy DirectorAlcon Research, LLC

Media Library

Clareon Toric IOL (Intraocular Lens) Clinical Trial Eligibility Overview. Trial Name: NCT05481125 — N/A
Cataract Research Study Groups: Clareon/Clareon Toric, Eyhance/Eyhance Toric
Cataract Clinical Trial 2023: Clareon Toric IOL Highlights & Side Effects. Trial Name: NCT05481125 — N/A
Clareon Toric IOL (Intraocular Lens) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05481125 — N/A
~64 spots leftby Dec 2025